Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMAG OTCMKTS:IPHYF NASDAQ:KIN NYSE:LCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AIPHYFInnate Pharma$1.31$1.56$1.31▼$1.95$109.82M0.538 shsN/AKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IPHYFInnate Pharma0.00%0.00%-24.50%-9.66%-32.13%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%LCILannett0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAGAMAG Pharmaceuticals 0.00N/AN/AN/AIPHYFInnate Pharma 0.00N/AN/AN/AKINKindred Biosciences 0.00N/AN/AN/ALCILannett 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87IPHYFInnate Pharma$21.77M5.04N/AN/A$0.11 per share11.91KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29LCILannett$340.58M0.00N/AN/A($23.34) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/AIPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ALCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAGAMAG Pharmaceuticals1.131.751.45IPHYFInnate PharmaN/A2.602.60KINKindred Biosciences0.197.027.02LCILannettN/A2.231.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAGAMAG PharmaceuticalsN/AIPHYFInnate PharmaN/AKINKindred Biosciences66.89%LCILannett40.28%Insider OwnershipCompanyInsider OwnershipAMAGAMAG Pharmaceuticals12.73%IPHYFInnate Pharma31.89%KINKindred Biosciences13.69%LCILannett13.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableKINKindred Biosciences6345.46 millionN/AOptionableLCILannett81010.77 million9.35 millionOptionableIPHYF, AMAG, KIN, and LCI HeadlinesRecent News About These CompaniesDespite Recent Weak Spots, LCI Industries Is Still Appealing At Current PricesJanuary 17, 2025 | seekingalpha.comCompleting a successful tech transferAugust 16, 2024 | pharmaphorum.comPThe pharma trends leading to higher demand for CDMOsAugust 10, 2024 | pharmaphorum.comPLevothyroxine Dosage and the Limitations of Current Bioequivalence StandardsApril 7, 2024 | medscape.comM‘We lost a good friend;’ Coweta County deputy ran over, killed by Alabama officer identifiedJanuary 6, 2024 | wsbradio.comWInsider Traders Made Easy Money on Stock OfferingsOctober 2, 2023 | tradersmagazine.comTLucky Core Industries Ltd.September 20, 2023 | wsj.comLannett (LCI) Stock Sinks on Lowered Guidance, Canaccord DowngradeSeptember 15, 2023 | thestreet.comGeneric-Drugs Antitrust Case Expanded to Include 18 CompaniesAugust 2, 2023 | courthousenews.comCLannett official: Bankruptcy won’t affect Seymour facilityMay 12, 2023 | tribtown.comTLannett official: Bankruptcy won't affect Seymour facility - Seymour TribuneMay 12, 2023 | news.google.comNSocietal CDMO Reports First Quarter 2023 Financial Results - Yahoo FinanceMay 11, 2023 | news.google.comNLannett files prepackaged Chapter 11 cases - Drug Store NewsMay 11, 2023 | news.google.comNVolunteers complete projects for Jackson County United Way’s 27th ... - Seymour TribuneMay 10, 2023 | news.google.comNAround the nation: Biden administration warns against medical ... - The Daily BriefingMay 9, 2023 | news.google.comNGlobal Methylphenidate Drug Market Size Emerging Trends and Will ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comNGlobal Drugs of UDCA Market Size Analysis, Share, Application ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNErgocalciferol Market Statistical Forecast, Trade Analysis 2023 - Sanofi S.A., Orit Laboratories LLC, Lannett - openPRMay 8, 2023 | news.google.comNGeneric Drugmaker Lannett Hits Ch. 11 With $700M In Debt - Law360May 5, 2023 | news.google.comNPadagis Achieves A US First With Budesonide Foam Launch - Generics BulletinMay 5, 2023 | news.google.comNMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Stocks With Near-Unanimous Buys That Could Rally HigherBy Nathan Reiff | July 2, 2025View 3 Stocks With Near-Unanimous Buys That Could Rally HigherForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideIPHYF, AMAG, KIN, and LCI Company DescriptionsAMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Innate Pharma OTCMKTS:IPHYF$1.31 0.00 (0.00%) As of 07/16/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
